Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Future Oncology (London, England)|March 16, 2021
Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registryArne Strauss, Marianne Schmid, Michael Rink, et al.
Future Oncology (London, England)|October 6, 2020
Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registryMartin Boegemann, Katrin Schlack, Michael Rink, et al.
The Prostate|February 17, 2016
See the unseen: Mesorectal lymph node metastases in prostate cancerSameh Hijazi, Birgit Meller, Conrad Leitsmann, et al.
Oncology Research and Treatment|January 19, 2022
A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study)Viktor Grünwald, Thomas Hilser, Johannes Meiler, et al.
European Radiology|September 27, 2018
Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysisJohannes Uhlig, Arne Strauss, Gerta Rücker, et al.
Urologia Internationalis|July 13, 2017
Oncologic Response and Hospitalization Rate of Patients Receiving Cabazitaxel in the Fourth-Line and Beyond in Castration-Resistant Prostate Cancer: Analysis of a Retrospective Cohort and a Structured Literature ReviewJost von Hardenberg, Maike Schwartz, Thorsten Werner, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|June 10, 2009
The impact of prostate volume changes during external-beam irradiation in consequence of HDR brachytherapy in prostate cancer treatmentMarkus Karl Alfred Herrmann, Tammo Gsänger, Arne Strauss, et al.
Radiation Oncology (London, England)|February 22, 2012
Gold marker displacement due to needle insertion during HDR-brachytherapy for treatment of prostate cancer: a prospective cone beam computed tomography and kilovoltage on-board imaging (kV-OBI) studyMarkus K A Herrmann, Tereza Kertesz, Tammo Gsänger, et al.
The Canadian Journal of Urology|June 19, 2012
Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastasesUlf W Tunn, Amulf Stenzl, Wolfgang Schultze-Seemann, et al.
Current Oncology (Toronto, Ont.)|June 25, 2025
Dosimetric Comparison of VMAT Alone and VMAT with HDR Brachytherapy Boost Using Clinical and Biological Dose Models in Localized Prostate CancerManuel Guhlich, Olga Knaus, Arne Strauss, et al.
Pageof 4